Close Menu

BioReference Laboratories

In announcing a national emergency on Friday, Trump paraded out executives from the private sector as the administration tries to increase testing capacity

BioReference is also now accepting specimens for testing SARS-CoV-2 and expects to offer 5,000 tests a day at satellite testing sites next week.

LabCorp's test is being made available pursuant to FDA guidance that allows high-complexity, CLIA-certified labs to perform their own tests for SARS-CoV-2.

A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.

 

A study of 10 commercial labs offering NIPT in the US found that none followed all recommendations for reporting results and informing patients and providers.

BioReference Lab's GenPath division will notify treating oncologists when a genomic alteration is detected that matches an NCI-MATCH treatment arm.

Seventeen organizations don't support the Diagnostic Accuracy and Innovation Act as written and would like lawmakers to advance a CLIA-centric framework.


The partners are planning to conduct meta-analyses of shared exome datasets from patients with inherited neurological disorders.

Opko subsidiary Bio-Reference Laboratories is retiring GeneTests.org next month given the availability of the NIH-backed Genetic Testing Registry.

The alliance will combine the two firms' technologies and know-how to provide doctors with insights into patients' health status.

Pages

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.